Lifecore Biomedical
LFCR
96 hedge funds and large institutions have $265M invested in Lifecore Biomedical in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 40 reducing their positions, and 11 closing their positions.
28% more capital invested
Capital invested by funds: $206M → $265M (+$58.4M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
1.58% more ownership
Funds ownership: 91.76% → 93.34% (+1.6%)
1% more funds holding
Funds holding: 95 → 96 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less call options, than puts
Call options by funds: $12K | Put options by funds: $14K
33% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
+$5.62M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.35M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.77M |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$2.84M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$3.24M |
| 2 |
RA
Royce & Associates
New York
|
-$2.86M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$2.04M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$1.65M |
| 5 |
Morgan Stanley
New York
|
-$1.33M |
LFCR Hedge Fund Activity: Q3 2020 in Review
96 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2020, worth a combined $265M — up 28% from $206M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LFCR positions and 11 closed out — a net gain of 2 holders — while 27 added to existing stakes and 40 trimmed.
The largest buyer was Cove Street Capital, adding an estimated $5.62M. The largest seller was NWQ Investment Management Company, cutting an estimated $3.24M.
- 96 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2020, up from 95 in Q2 2020.
- Funds reported $265M of Lifecore Biomedical stock for Q3 2020, up 28% quarter-over-quarter.
- 13 funds opened new Lifecore Biomedical positions in Q3 2020 and 11 closed out, a net change of +2 holders.
- The largest Lifecore Biomedical buyer in Q3 2020 was Cove Street Capital, an estimated $5.62M added.
- The largest Lifecore Biomedical seller in Q3 2020 was NWQ Investment Management Company, an estimated $3.24M sold.
Based on aggregated 13F filings for Q3 2020.